Current status of therapy for human immunodeficiency virus type 1.
The past year has been refinement in our ability to delay the progression of human immunodeficiency virus type 1 infection through the use of nucleoside analogues, singly or in combination. Progress has also been made in our ability to detect drug-resistant isolates of human immunodeficiency virus type 1 and to begin to put the laboratory observations of resistance into a clinical context.
Lane
H C
HC
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016049:Didanosine / Q000627:therapeutic use*; D004351:Drug Resistance; D015658:HIV Infections / Q000188:drug therapy*; D006679:HIV Seropositivity; D015497:HIV-1; D006801:Humans; D006377:T-Lymphocytes, Helper-Inducer; D016047:Zalcitabine / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use*
D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine